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Abstract 
Several methodological approaches suggest receptor heteromers exist in cell systems, but 
their presence in physiological tissue is widely contentious.  We describe a novel method to 
determine if heterodimers exist in brain tissue sections using autoradiographic binding 
comparisons from single and double gene knockout mice, where tissues either have a full 
receptor complement and can form heterodimers, or are incapable of making heterodimers. 
We have tested this model, which we have named Knockout Subtraction Autoradiography, to 
determine if heterodimerisation of the kappa (KOPr) and delta (DOPr) opioid receptors 
occurs, as evidence from binding studies in cell systems suggest they are present in the brain.  
Using labeling of putative KOPr/DOPr heterodimers with either [
3
H] bremazocine or with 
[
3
H] naltrindole, two ligands which were used to provide evidence suggesting that these 
opioid receptor subtypes heterodimerize, we have applied a subtraction equation model based 
on the principle that receptor gene double knockout of either MOPr/KOPr (DOPr expression 
only) or MOPr/DOPr (KOPr expression only) produces tissue incapable of making the 
KOPr/DOPr heterodimer.  Should heterodimers exist, binding profiles from these should 
differ from tissues with a full receptor complement.  We have shown in most brain regions 
the labeling fits a simple additive model of monomer labeling, but that in a few brain regions 
opioid receptor heterodimerization does occur.  The data does not support the conclusion that 
KOPr/DOPr heterodimerisation is widespread in the central nervous system, but does indicate 
this novel methodology can detect heterodimerisation, when ligands with distinct binding 
affinities for monomer and heterodimer forms exist. 
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Abbreviations: 
 
AcbC, Nucleus accumbens core; AcbSh, Nucleus accumbens shell; Amy, Amygdala; BRET, 
bioluminescence resonance energy transfer; Cg, Cingulate cortex; Cl, Claustrum; CPu, 
Caudate putamen; DEn, Dorsal endopiriform nucleus; DOPr, delta opioid receptor; FRET, 
fluorescence resonance energy transfer; GPCRs, G-protein coupled receptors; Hip, 
Hippocampus; Hyp, Hypothalamus; IP, Interpeduncular nucleus; KO, knockout; KOPr, 
kappa opioid receptor; KSA, Knockout Subtraction Autoradiography; MCx, Motor cortex; 
MHb, Medial habenular nucleus; MOPr, mu opioid receptor; OB, Olfactory bulb; PAG, 
Periaqueductal gray; PCR, polymerase chain reaction; PrL, Prelimbic cortex; SN, Substantia 
nigra; SuG, Superficial gray layer of the superior colliculus; Th, Thalamus; Tu, Olfactory 
tubercle; VTA, Ventral tegmental area; WT, wild-type 
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1. Introduction 
Opioid receptors belong to the superfamily of G-protein coupled receptors (GPCRs) and were 
originally believed to be present as monomeric entities, but like many other GPCR families 
current thinking suggests they form heteromers that modulate the physiological and 
pharmacological function of the receptor (Gurevich and Gurevich, 2008). Cell studies over 
more than a decade have suggested that mu opioid receptors (MOPr) and delta opioid 
receptors (DOPr), as well as kappa opioid receptors (KOPr) and DOPr may exist as 
heteromers (Gomes et al., 2004; Gomes et al., 2000; Jordan and Devi, 1999). In cell studies, 
co-expression of KOPr/DOPr heteromers (Jordan and Devi, 1999) or MOPr/DOPr 
heteromers (Gomes et al., 2004; Gomes et al., 2000) exhibited distinct ligand binding and 
signaling characteristics compared to cells individually expressing the monomeric form of 
these receptors, suggesting dimerisation between the different subtypes of opioid receptors 
could modulate receptor function.  More recent studies have focused on conditions that might 
drive the process of opioid heterodimerisation and evidence has been provided that chronic 
morphine treatment increases the abundance of heteromers (Gupta et al., 2010), which might 
be of relevance to the treatment of addiction disorders (Stockton and Devi, 2012).  Moreover 
for other G-protein coupled receptors (e.g dopamine and adenosine) there is evidence that 
implicates heteromer dysfunction in diseases such as depression (Pei et al., 2010) and 
schizophrenia (Faron-Górecka et al., 2008).   
 
Whilst several methods have been developed to investigate oligomerisation of GPCRs in 
vitro (Harrison and van der Graaf, 2006), including biochemical (co-immunoprecipitation and 
western blotting), biophysical (fluorescence resonance energy transfer, FRET and 
bioluminescence resonance energy transfer, BRET) and pharmacological (competitive ligand 
binding) approaches, only one method in intact physiological tissue has to date been 
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advanced (Gupta et al., 2010).  This has led most recently to the development of a cell based 
system using fusion proteins that may be used as a novel screening assay for detecting 
heteromer signaling (van Rijn et al., 2013), demonstrating potency differences of some 
ligands for the monomer and heteromer forms of the DOPr and MOPr receptors  
 
In the original paper demonstrating opioid heterodimerisation, Jordan and Devi (1999) 
provided pharmacological evidence for the existence of heteromer forms of the KOPr and the 
DOPr in vitro.  In a cell culture study they showed co-immunoprecipitation and distinct 
ligand binding profiles of co-expressed KOPr and DOPr in HEK cells proposing that these 
receptors heterodimerise.  In the cell studies, (5α,7α,8β)-N-methyl-N-[7-(1-pyrrolidinyl)-1-
oxaspiro[4,5]dec-8-yl]benzeneacetamide (U-69,593), a selective ligand for the KOPr and [D-
Ala
2
,D-Leu
5
]enkephalin (DPDPE), a selective ligand for the DOPr, were shown to be  
inactive at the KOPr/DOPr heteromer, whereas [
3
H]bremazocine (a putative ligand that is 
thought to bind to KOPr/DOPr heteromer) had a 3-fold lower affinity for the KOPr/DOPr 
heteromer than for the KOPr monomer, but a 6-fold higher for the DOPr monomer compared 
to the KOPr/DOPr heteromer  (Jordan and Devi, 1999). They also showed that the selective 
DOPr-selective antagonist, naltrindole, had a 40 fold lower affinity for the KOPr/DOPr 
heteromer than for the DOPr, but was equipotent at the KOPr monomer.  
 
To determine if such heterodimerisation occurs in physiological tissue as well as in cell 
systems we have hypothesised that quantitative receptor autoradiography with 
[
3
H]bremazocine and [
3
H]naltrindole could be used to show binding to a monomer and 
heteromer form of the KOPr and the DOPr if binding was carried out in single and 
combinatorial opioid receptor knockout (KO) mice.  The approach, which we have named 
Knockout Subtraction Autoradiography (KSA) (Fig. 1A) is based on the principle that 
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receptor gene double knockout of either MOPr/KOPr (DOPr expression only) or MOPr/DOPr 
(KOPr expression only) produces tissue incapable of making the KOPr/DOPr heterodimer. 
Should heterodimers exist, binding profiles from these should differ from tissues with a full 
receptor complement.  We used [
3
H]bremazocine, and [
3
H]naltrindole to label the receptor 
forms of the KOPr and DOPr, respectively, two ligands which provided key in vitro evidence 
suggesting that these opioid receptor subtypes heterodimerize (Jordan and Devi, 1999).  The 
data shows that heterodimerisation of KOPr and DOPr can be observed in brain slice sections, 
but that across a wide range of anatomical structures throughout the mouse brain the KOPr 
and the DOPr exist predominantly in monomeric forms. 
 
2. Materials and Methods 
2.1 Animals 
2.1.1. Single MOPr, double MOPr/DOPr and MOPr/KOPr knockout mice 
Mice lacking MOPr (Matthes et al., 1996), DOPr (Filliol et al., 2000) and KOPr (Simonin et 
al., 1998) were generated in Prof Kieffer’s laboratory (IGBMC-CERBM, France). Breeding 
pairs of single MOPr and double homozygous (MOPr/DOPr and MOPr/KOPr) KO mice, 
maintained on a pure C57BL/6 genetic background, were obtained from hybrid mutant mice 
by interbreeding of single knockout strains, originally created on a mixed of C57BL/6J and 
129Sv background.  Congenic C57BL/6 MOPr, MOPr/DOPr and MOPr/KOPr KO mice were 
derived following at least 10 generations of successive backcrossing of 129Sv × C57BL/6 
heterozygotes to C57BL/6 mice.  Animals used in this study were between 32 and 45 weeks 
old adult male (WT: n=3, MOPr KO: n=4, MOPr/KOPr KO: n= 3 and MOPr/DOPr KO: n=4) 
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and female (WT: n=3, MOPr KO: n=2, MOPr/KOPr KO: n= 3 and MOPr/DOPr KO: n=2) 
mice and were genotyped by PCR at weaning.   
 
2.1.2. Triple opioid receptor knockout mice 
As described previously by Simonin el al. (2001), triple mutant mice lacking MOPr, DOPr 
and KOPr genes were generated by interbreeding of single MOPr (Matthes et al., 1996), 
DOPr (Filliol et al., 2000), and KOPr (Simonin et al., 1998) KO mice.  In brief, double 
MOPr/DOPr KO mice (50% C57BL/6 and 50% 129S2) were mated with double MOPr/KOPr 
KO mice (50% C57BL/6 and 50% 129S2) to generate triple opioid receptor KO mice 
maintained on a mixed background (50% C57BL6/J and 50% 129S2).  Both the triple opioid 
receptor KO and wild-type (WT) mice are on a mixed C57BL/6J and 129Sv background.  
Animals used in this study were between 21 and 23 weeks old adult male and female mice 
and were genotyped by PCR at weaning.  All experiments were carried out in accordance 
with the European Communities Council Directive of 24 November 1986. 
 
2.2. Materials  
[
3
H]Bremazocine (26.5 Ci/mmol) was purchased from New England Nuclear (Boston, MA, 
USA).   [
3
H]naltrindole (40.6 Ci/mmol) was synthesized by Dr. G  a   th,  Dr. Anna 
Borsodi and Dr. Sandor Benyhe at the Hungarian Academy of Sciences, Szeged.  Naloxone 
was purchased from Sigma-Aldrich (Sigma-Aldrich Company Ltd., Dorset, UK).  
 
2.3. Autoradiography 
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Animals were killed and the brains were immediately removed and snap frozen at -20 °C in 
isopentane for 30 sec.  Brains were subsequently stored at -80 °C for a maximum period of 
one month before sectioning.  Coronal sections (20 μm) were cut at 300 μm intervals from 
fore to hindbrain onto precleaned and subbed microscope slides (Kitchen et al., 1997) from 
single MOPr, double MOPr/DOPr and MOPr/KOPr.  Sagittal sections (20 μm) were cut from 
triple opioid receptor KO and W  at an interval of 300 μm to assess the levels of binding 
throughout forebrain to hindbrain structures.  
All slides were preincubated in 50 mM Tris-HCl, pH 7.4, plus 0.9 % NaCl for 30 min, to 
remove endogenous opioids (Kitchen et al., 1997). The concentration of [
3
H]bremazocine (2 
nM) and [
3
H]naltrindole (1 nM)  was chosen from previous autoradiographic binding studies 
in wild-type mice to represent a level approaching a receptor saturating concentration 
(Kitchen et al., 1997; Oakley et al., 2003; Simonin et al., 2001).  Quantitative 
autoradiographic binding of the ligands was carried out in 50 mM Tris-HCl, pH 7.4, at room 
temperature for 60 min in brains of WT and mice lacking either MOPr, MOPr/KOPr or 
MOPr/DOPr as well as in mice lacking all three classical opioid receptors. Non-specific 
binding was determined by adding 10 μM naloxone.  Slides were washed 3 times with ice-
cold Tris-HCl buffer, pH 7.4, for 5 min and rapidly cool-air dried.  
 
Autoradiograms were generated by apposing the labelled tissue sections to Kodak BioMax 
MR films (Eastman Kodak Co., Rochester, NY, USA).  Cassettes were sealed using opaque 
tape to prevent light entry and stored in a dark place for a period of 6 to 9 weeks in X-ray 
film cassettes along with Amersham tritiated polymer standards at room temperature. Kodak 
BioMax MR films were developed in 50 % Kodak D19 developer solution.  Sections from 
WT and KO animals were processed together at all stages of experimental procedures to 
ensure a paired protocol for binding, film apposition and image analysis. 
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All films were analysed by video-based computerized densitometry using an MCID image 
analyser (Imaging Research, Canada) as previously described (Kitchen et al., 1997).  Films 
were placed onto a light box (Kaiser Pro-lite, Germany) and calibration took place using the 
exposed images of the tritium microscale standards.  Brain regions were analyzed in duplicate 
for each brain using left and right hemispheres. The cortical structures and the olfactory 
tubercle were analyzed by sampling 5-20 times with a box tool (2  2 mm). All other regions 
were analyzed by freehand drawing tools.  Structures were identified by reference to the 
mouse atlas of Franklin & Paxinos (2001) (Franklin and Paxinos, 2001).  Specific binding 
was calculated by subtracting the level of non-specific binding from the total binding level. 
 
Confirmation of the PCR genotyping was carried out by autoradiographic labeling of MOPr, 
DOPr and KOPr with receptor selective ligands as described in our previous studies (Kitchen 
et al., 1997), and was also used to determine any compensatory changes in each remaining 
opioid receptor in combinatorial knockouts. 
 
2.4. Data analysis 
Comparison of specific binding of either [
3
H]bremazocine and [
3
H]naltrindole in MOPr, 
double MOPr/DOPr and MOPr/KOPr KO mice was made using the equations described in 
Figure 1A.  A model was developed to test statistically whether, within experimental error, 
across the set of the component values for the KSA equation, the value for the MOPr KO was 
distinguishable from the sum of the remaining two.  For each triplet of values, the difference 
of the MOPr KO value from the sum of the remaining two was formed. The resultant set of 
differences was subjected to a null ANOVA model using PROC MIXED of the SAS suite of 
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programs (SAS Institute, Cary, NC, USA), both with intercept included and, separately, with 
intercept excluded.  A 1 degree of freedom chi-squared test applied to the difference of the 
resultant two deviance model-goodness-of-fit measures, for the statistical significance of 
including the intercept, yielded the desired test of additivity within the triples.  P values <0.05 
demonstrated significant deviation from a model of additivity, indicative of heterodimer 
labeling. 
 
3. Results 
 
Coronal brain sections were cut from single MOPr (DOPr and KOPr present, both monomers 
and potential heterodimers), or double MOPr/KOPr (DOPr only, monomers) and 
MOPr/DOPr (KOPr only, monomers) KO mice.  [
3
H]bremazocine and [
3
H]naltrindole 
binding were measured at a single ligand concentration which in our previous 
autoradiographic binding experiments represents a near saturation concentration (Oakley et 
al., 2003; Simonin et al., 2001). If binding of the ligands used in this study is to monomer 
forms of the KOPr and DOPr, then binding from the equation MOPr KO − MOPr/KOPr KO 
= MOPr/DOPr KO should apply (Fig. 1A, upper panel).  However if binding of these ligands 
is to heterodimer forms then MOPr KO − MOPr/KOPr KO  MOPr/DOPr KO should apply 
(Fig. 1B lower panel).  We have used a statistical analysis of additivity to determine in each 
brain region studied if binding is, or is not, additive.  
 
3.1. [3H]Bremazocine binding in wild-type, MOPr, MOPr/DOPr and MOPr/KOPr 
knockout mice 
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 [
3
H]Bremazocine binding was higher in all brain regions of WT mice compared to single 
MOPr KO, double MOPr/DOPr and MOPr/KOPr KO mice demonstrating some labeling to 
all three opioid receptors  (Fig. 1B). In MOPr KO, high levels of binding were detected in 
several regions showing substantial binding of this ligand to KOPr and DOPr (Fig. 1B).  
When quantitative subtraction (Fig. 1C and Table 1) was applied to the [
3
H]bremazocine 
binding results obtained from single MOPr KO and double MOPr/KOPr and MOPr/DOPr 
KO mice the subtraction binding fitted best to the monomer model (MOPr KO − 
MOPr/KOPr KO = MOPr/DOPr KO) in twenty brain regions.  Only two brain regions 
(olfactory bulb and periaqueductal gray) approached statistical significance for lack of 
additivity (P<0.09, Table 1).  
 
3.2. [3H]naltrindole binding in wild-type, single and double opioid receptor knockout 
mice 
[
3
H]Naltrindole binding was similar in many brain regions of WT and MOPr KO mice 
showing only a small amount of labeling of the MOPr by this ligand (Fig. 2A). Binding in 
double MOPr/KOPr KO mice was markedly higher than in MOPr/DOPr KO mice in several 
forebrain structures signifying high DOPr monomeric labeling (Fig. 2A).  When quantitative 
subtraction (Fig. 2B and Table 1) was applied to the [
3
H]naltrindole binding results obtained 
from single MOPr KO and double MOPr/KOPr and MOPr/DOPr KO mice, the subtraction 
binding fitted best to the monomer/homo-oligomer model (MOPr KO − MOPr/KOPr KO = 
MOPr/DOPr KO) in twelve out of fifteen regions examined (Fig. 2B and Table 1).  Three 
regions however (thalamus, amygdala and interpeduncular nucleus) showed a best fit to the 
heterodimer/hetero-oligomer model with highly significant differences from simple additivity 
(Fig. 2B and Table 1).  The hippocampus also approached statistical significance (P<0.07).  
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3.3. [3H]bremazocine and [3H]naltrindole binding and compensatory changes in 
single and combinatorial knockout brains 
 
Deletion of both single and double receptor knockout produces minor changes in the 
remaining opioid receptor complements and we have historical (Kitchen et al., 1997) and 
unpublished data for all of the brain regions studied using the KSA approach.  We therefore 
made corrected adjustments to the raw binding data for each brain region for both 
[
3
H]bremazocine and [
3
H]naltrindole binding.  The data corrected for compensatory changes 
is shown in Table 2 and shows a very similar pattern to the binding differences presented in 
the raw data histograms (Fig. 1C and Fig. 2B).   The corrected values (Table 2) did not alter 
the monomer/heteromer fit analysis confirming that where significant deviation from 
additivity had been observed this was also robust if compensatory changes in the gene 
knockout models were accounted for.  
 
3.4. [3H]bremazocine and [3H]naltrindole binding in triple opioid receptor knockout 
mice 
Triple opioid receptor KO mice were used to confirm whether both ligands studied bind to 
other receptors in addition to all three classical opioid receptors.  No specific 
[
3
H]bremazocine or [
3
H]naltrindole binding was detected in the sagittal brain sections of mice 
lacking the three classical opioid receptor genes confirming the ligands can only bind to the 
three classical opioid receptors (Fig. 3). 
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4. Discussion  
 
Although several methods such as FRET, BRET, ligand binding, co-immunoprecipitation and 
Western blotting have been developed to investigate the existence of 
heterodimer/heteroligomers in vitro (Gomes et al., 2004; Gomes et al., 2000; Harrison and 
van der Graaf, 2006; Jordan and Devi, 1999), proving the existence of heteromers in 
physiological systems has been a more challenging task.  Gupta et al. (2010) using a 
subtractive immunization strategy to generate antibodies to selectively recognize 
MOPr/DOPr heteromers have been able to show that chronic morphine treatment leads to 
increased heterodimer formation in endogenous brainstem neurons.  However, concern over 
the limitations of immunization techniques, particularly in relation to lack of reliability of 
antibody selectivity, makes alternative approaches attractive.  The model described in our 
study has aimed, using a subtractive receptor binding model, to determine if KOPr/DOPr 
heterodimers are widespread in brain tissue.  The model is based on the principle that 
receptor KO of either KOPr of DOPr produces tissue incapable of making heteromers, and 
when compared to tissues with a full receptor complement should show different binding 
profiles if heterodimerisation exists.   
 
In the KSA model it is prudent to consider whether compensatory changes of other opioid 
receptors, which may occur due to the deletion of single or double opioid receptors, might 
influence the additivity analysis. As deletion of both single and double receptor knockout 
produces only minor changes in the remaining opioid receptor complements the corrected 
adjustments to the raw binding data made little material alteration to the monomer/heteromer 
fit analysis. Thus, the observed [
3
H]bremazocine and [
3
H]naltrindole binding in single MOPr, 
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double MOPr/DOPr and MOPr/KOPr KO mice are not influenced to any great extent by 
compensatory changes occurring due to the deletion of genes for the receptors. This lack of 
compensatory changes in single and double opioid receptor knockout mice makes analysis by 
KSA robust for opioid receptor systems, and this would be an important validation criteria for 
using the model for other G-protein coupled receptor systems. We also confirmed using triple 
opioid receptor KO mice that both ligands studied bind only to all three classical opioid 
receptors.  Again selectivity of binding to only the receptors involved in the 
heterodimerisation activity would be a key criteria for use of KSA for other receptor families.  
 
One limitation of the autoradiographic method to detect heterodimers is the achievable 
resolution, and the lack of ability to take into account the level of individual receptor and 
study at the single cell levell.  . Although the KSA method cannot provide molecular 
mechanisms underpinning DOPr/KOPr heterodimer/hetero-oligomer formation it can infer 
the presence or absence of the heterodimer in a physiological system, which is a useful 
starting point to address specific regional experiments that could be carried out to confirm 
molecular co-localisation.  As binding properties (Kd, Bmax) of bremazocine and naltrindole 
at the MOPr, DOPr, KOPr and their heterodimers differ considerably (Jordan and Devi, 
1999), we are confident that these concentrations of radioligand would be adequate to detect 
heterodimers, should they exist.  Although we failed to find evidence for widespread 
heterodimerisation in normal tissue the potential role for heteromers in mouse models of 
disease states (Pei et al., 2010), or after chronic drug treatment (Gupta et al., 2010) should be 
recognized.  Indeed using KSA after treatment conditions might be another approach to 
address the importance of heterodimerisation after disease or chronic treatment intervention. 
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In conclusion, using the KSA approach our data shows only sparse heterodimerization of 
KOPr and DOPr’s across several brain regions.  In line with our findings, a role for opioid 
heterodimers in modulating the actions of opioid drug actions requires their co-expression in 
a single cell, a concept that is controversial and a previous study has failed to find DOPr’s, 
fused with enhance green fluorescent protein in MOPr containing small dorsal root ganglion 
neurons (Scherrer et al., 2009).  Despite the lack of evidence in our study for widespread 
heterodimerization throughout the brain, the importance of heterodimer formation in a few 
structures should not be underestimated, and the potential functional role for 
heterodimerisation in thalamus and amygdala may point to their relevance in pain and 
emotional behaviours.  Pharmaceutical interest in heterodimers is driven by the realization 
that agonist drugs could differentially target these structures and indeed if this occurs in a few 
target brain regions then this could be extremely advantageous. The KSA technique does 
have the potential for studying heterodimerization of all GPCRs where appropriate single and 
double knockout tissue is available and could be used to screen for heterodimer interactions 
of existing and new chemical entities. 
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Table 1. Probability values for [
3
H]bremazocine and [
3
H]naltrindole binding 
 
    P value 
Region   [
3
H]Bremazocine [
3
H]Naltrindole 
Olfactory bulb  0.0882 0.3619 
Prelimbic cortex 0.7480  - 
Caudate putamen 0.9990 0.2701 
Nucleus accumbens core 0.7635 0.5237 
Nucleus accumbens shell 0.5729 0.4662 
Olfactory tubercle 0.6001 0.9450 
Claustrum 0.1921 0.3285 
Dorsal endopiriform nucleus 0.8875 0.9574 
Cingulate cortex 0.7985 0.3776 
Motor cortex 0.2736  - 
Hippocampus 0.9410 0.0692 
Thalamus 0.8501 0.0192 
Hypothalamus 0.6542 0.5716 
Amygdala 0.8009 0.0142 
Medial habenular nucleus 0.5805  - 
Substantia nigra 0.1066 0.1208 
Ventral tegmental area 0.7067 0.2217 
Interpeduncular nucleus 0.5674 0.0265 
Periaqueductal gray 0.0859  - 
Superficial gray layer of the superior colliculus 0.3575  - 
 
 
Legend to table 1 
Probability values for [
3
H]bremazocine and [
3
H]naltrindole binding tested for fit to a 
model of additivity in several brain regions as described in the methods.  For 
[
3
H]bremazocine  binding, no region showed significant (P<0.05) deviation from an 
additivity model showing binding best fits monomer labeling throughout the brain 
(see Figure 1C). For [
3
H]naltrindole binding three regions (Thalamus, Amygdala and 
Interpeduncular nucleus) showed significant (P<0.05) deviation from an additivity 
model showing best fit to heterodimer labeling in these regions and monomer labeling 
in all other regions (see Figure 2B)
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Table 2. Compensated values for [
3
H]bremazocine and [
3
H]naltrindole binding 
 
  [
3
H]Bremazocine   [
3
H]Naltrindole 
Region MOPr -/- MOPr/KOPr -/- MOPr/DOPr -/-   MOPr -/- MOPr/KOPr -/- MOPr/DOPr -/- 
Olfactory bulb  124.4 129.8 29.6 
 
151.0 137.8 12.2 
Caudate putamen 142.4 106.8 43.2 
 
79.0 67.2 8.3 
Nucleus accumbens core 104.7 34.3 51.5 
 
42.3 12.7 13.5 
Nucleus accumbens shell 107.0 25.2 51.9 
 
36.7 6.6 9.8 
Olfactory tubercle 122.8 70.8 60.6 
 
69.9 53.4 14.1 
Claustrum 207.1 70.3 174.1 
 
50.6 30.6 17.7 
Cingulate cortex 89.3 75.3 23.1 
 
59.6 63.1 9.6 
Hippocampus 34.1 26.3 7.8 
 
30.8 33.1 5.9 
Thalamus 45.5 22.9 21.5 
 
13.0 18.8 9.8 
Hypothalamus 77.9 14.7 55.4 
 
11.2 7.1 7.5 
Amygdala 76.7 39.6 34.4   29.4 36.1 11.0 
 
Legend to table 2 
Table 2 shows the binding levels (fmol/mg tissue) for [
3
H]bremazocine and [
3
H]naltrindole binding in MOPr KO, MOPr/DOPr KO and 
MOPr/KOPr KO mice after correction for compensatory changes in gene knockout mice have been applied. The compensatory changes in 
monomeric DOPr and KOPr in brain regions of single and double opioid receptor KO mice were applied to absolute values (Figures 1C and 2B) 
in order to obtain the corrected values (Table 2). The observed [
3
H]bremazocine and [
3
H]naltrindole binding in single MOPr (n=6), double 
MOPr/DOPr (n=6) and MOPr/KOPr (n=6) KO mice were not signficantly influenced by compensatory changes occurring due to the deletion of 
genes for the receptors and the model of additivity revealed the equivalent analysis as for the uncorrected values.  
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Figure legends 
 
Figure 1.  (A)  Model showing quantitative subtraction equation to identify monomer or 
heterodimer binding in single and double opioid receptor knockout (KO) mice.  If binding of 
[
3
H]bremazocine or [
3
H]naltrindole is to monomer/homo-oligomer forms of the KOPr and 
DOPr then binding from the equation MOPr KO − MOPr/KOPr KO = MOPr/DOPr KO  
should apply (A; upper row).  However if binding of [
3
H]bremazocine or [
3
H]nor-BNI is to 
heterodimer/ hetero-oligomer forms then MOPr KO − MOPr/KOPr KO  MOPr/DOPr KO 
should apply (A; lower row).  (B) Representative pseudo-colour images showing 
[
3
H]bremazocine (2nM) binding in brains of wild-type (WT), single MOPr and double 
MOPr/KOPr and MOPr/DOPr KO mice at the level of the caudate and hippocampus. Non-
specific binding (NSB) was determined in the presence of 10 μM of naloxone.  The colour 
bar represents pseudo-colour interpretation of black and white film images in fmol/mg tissue. 
(C)  Quantitative autoradiography of [
3
H]bremazocine (2 nM) binding in the brains of WT 
(n=6), single MOPr KO (n=6), double MOPr/KOPr (n=6) and MOPr/DOPr (n=6) KO mice.  
Non-specific binding was determined in the presence of 10 μM of naloxone. Values are 
expressed as mean ± SEM of 6 mice.  
Abbreviations: AcbC, Nucleus accumbens core; AcbSh, Nucleus accumbens shell; Amy, 
Amygdala; Cg, Cingulate cortex; Cl, Claustrum; CPu, Caudate putamen; DEn, Dorsal 
endopiriform nucleus; DOPr, delta-opioid receptor; Hip, Hippocampus; Hyp, Hypothalamus; 
IP, Interpeduncular nucleus; KOPr, kappa-opioid receptor; MCx, Motor cortex; MHb, Medial 
habenular nucleus; MOPr, mu-opioid receptor; OB, Olfactory bulb; PAG, Periaqueductal 
gray; PrL, Prelimbic cortex; SN, Substantia nigra; SuG, Superficial gray layer of the superior 
colliculus; Th, Thalamus; Tu, Olfactory tubercle; VTA, Ventral tegmental area 
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Figure 2.  (A)  Representative pseudo-colour images showing [
3
H]naltrindole (1 nM) binding 
in brains of wild-type (WT), single MOPr and double MOPr/KOPr and MOPr/DOPr 
knockout (KO) mice Non-specific binding (NSB) was determined in the presence of 10 μM 
of naloxone. The colour bar represents pseudo-colour interpretation of black and white film 
images in fmol/mg tissue.  (B)  Quantitative autoradiography of [
3
H]naltrindole (1 nM ) 
binding in the brains of WT (n=6) , single MOPr KO (n=6), double MOPr/KOPr (n=6) and 
MOPr/DOPr (n=6) KO mice.  Non-specific binding was determined in the presence of 10 μM 
of naloxone.  Values are expressed as mean ± SEM of 6 mice.    
Abbreviations: AcbC, Nucleus accumbens core; AcbSh, Nucleus accumbens shell; Amy, 
Amygdala; Cg, Cingulate cortex; Cl, Claustrum; CPu, Caudate putamen; DEn, Dorsal 
endopiriform nucleus; DOPr, delta-opioid receptor; Hip, Hippocampus; Hyp, Hypothalamus; 
IP, Interpeduncular nucleus; KOPr, kappa-opioid receptor; MOPr, mu-opioid receptor; OB, 
Olfactory bulb; SN, Substantia nigra; Th, Thalamus; Tu, Olfactory tubercle; VTA, Ventral 
tegmental area 
 
Figure 3. Representative pseudo-colour images showing [
3
H]bremazocine (2 nM ) and 
[
3
H]naltrindole (1 nM ) binding in sagittal brain sections of WT and triple opioid receptor 
(MOPr/DOPr/KOPr) KO mice.  Non-specific binding (NSB) was determined in the presence 
of 10 μM of naloxone.   he colour bar represents pseudo-colour interpretation of black and 
white film images in fmol/mg tissue.  
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